Foehr Matthew W
- SEC CIK
- 0001237556
In the past year, 5 open-market sale filings worth $705.2K and no purchases.
Current role at each company
- OABI OmniAb, Inc.President and CEOas of Apr 7, 2026
- VKTX Viking Therapeutics, Inc.Directoras of Jan 5, 2026
- LGND Ligand Pharmaceuticals IncOther: Former Executive Officeras of Nov 3, 2022
- OmniAb Operations, Inc.CLO & Secretaryas of Nov 3, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $705.2K
- 5 filings
- Net
- −$705.2K
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Foehr Matthew W as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
OABI OmniAb, Inc.
President and CEO18 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2026 (view filing) | Apr 7 | Same day | Foehr Matthew WPresident and CEO | SSale | −19.2K | $1.49 | −$28.7K | −0.4%4.42M after | |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Foehr Matthew WPresident and CEO | SSale | −30.8K | $1.71 | −$52.7K | −0.7%4.40M after | |
| Feb 17, 2026 (view filing) | Feb 17 | Same day | Foehr Matthew WPresident and CEO | SSale | −20.8K | $1.70 | −$35.3K | −0.5%4.38M after | |
| Dec 9, 2025 (view filing) | Dec 8 | 1 day | Foehr Matthew WPresident and CEO | SSale | −13.7K | $1.96 | −$26.8K | −0.3%4.36M after | |
| Apr 7, 2025 (view filing) | Apr 7 | Same day | Foehr Matthew WPresident and CEO | SSale | −19.4K | $2.00 | −$38.8K | −0.5%3.80M after | |
| Feb 19, 2025 (view filing) | Feb 18-19 | 1 day | Foehr Matthew WPresident and CEO | SSale | −33.5K | $3.67 | −$123.0K | −0.9%3.78M after | 2 lots |
| Jan 22, 2025 (view filing) | Jan 21 | 1 day | Foehr Matthew WPresident and CEO | SSale | −41.8K | $3.24 | −$135.5K | −1.1%3.75M after | |
| Dec 10, 2024 (view filing) | Dec 9 | 1 day | Foehr Matthew WPresident and CEO | SSale | −13.6K | $4.13 | −$56.3K | −0.4%3.71M after | |
| May 28, 2024 (view filing) | May 24 | 4 days | Foehr Matthew WPresident and CEO | PPurchase | +240.0K | $4.42 | +$1.06M | +7.3%3.54M after | |
| Mar 25, 2024 (view filing) | Mar 22 | 3 days | Foehr Matthew WPresident and CEO | PPurchase | +225.0K | $5.19 | +$1.17M | +8.4%2.91M after |
VKTX Viking Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Foehr Matthew WDirector | SSaleCommon Stock, par value $0.00001 per share | −16.0K | $35.11 | −$561.8K | −10.8%132.0K after | |
| May 3, 2022 (view filing) | May 2 | 1 day | Foehr Matthew WDirector | PPurchaseCommon Stock, par value $0.00001 per share | +45.0K | $2.47 | +$111.2K | +67.9%111.3K after |
LGND Ligand Pharmaceuticals Inc
Other: Former Executive Officer3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2022 (view filing) | May 13 | Same day | Foehr Matthew WPresident and COO | PPurchase | +2.50K | $82.76 | +$206.9K | +1.5%173.4K after | |
| Nov 12, 2021 (view filing) | Nov 11 | 1 day | Foehr Matthew WPresident and COO | SSale | −11.2K | $163.02 | −$1.82M | −6.3%166.5K after | |
| Aug 5, 2021 (view filing) | Aug 4 | 1 day | Foehr Matthew WPresident and COO | SSale | −8.84K | $109.67 | −$969.5K | −5.1%164.4K after |